Skip to content

Massively multiplexed qPCR

2,000 cancer biomarkers.
One chip. 30 minutes.

NGS-scale tumor genotyping on a single qPCR chip, at the cost and speed of a routine lab test.

Request infoSee how it works

Order from
randomness.

Thousands of barcoded VibrantBeads fall at random into a microwell array, then resolve into a precise, addressable chip. 50,000 isolated reactions, each decoded by its color.

Every well,
its own reaction.

As amplification runs, each microreactor reports out. Column height is its PCR efficiency, and the imager reads all 50,000 wells in a single shot: thousands of qPCR curves, at once.

Precision oncology forces an impossible choice.

Targeted therapy depends on knowing a tumor’s mutations. Yet today every lab must trade breadth for speed and cost, so broad genomic testing reaches only a fraction of the patients it could help.

NGS

Comprehensive, but out of reach

Biomarkers
Thousands
Turnaround
~4 weeks
Cost
> $3,000

Conventional qPCR

Fast and cheap, but narrow

Biomarkers
1-3
Turnaround
< 2 hours
Cost
$200-1,000

Only ~2% of patients receive large-panel genetic testing, while an estimated 800,000 per year would benefit. VibrantBio closes that gap.

The Randomly Addressable Microreactor.

Two breakthroughs make 2,000-plex qPCR possible on one chip: a microfluidic array of 50,000 isolated reactors, and color-coded VibrantBeads that tell each reactor what it is testing.

RAM chip: 50,000 microreactors

A nanofabricated array packs 50,000 sealed wells onto a 4×4 cm chip. Each well isolates one reaction, so the same reporter dye works everywhere and thousands of tests run without interference.

VibrantBeads®: billions of color codes

Microbeads doped with up to 20 spectrally resolvable Raman probes generate over a billion unique barcodes. Each bead delivers a known primer pair and an address the imager can read.

10⁹+
possible barcodes
100×
narrower than fluorescence

How a test runs

  1. 01

    Barcode

    VibrantBeads® carry primer pairs and are tagged with narrow-linewidth Raman dyes, combined to yield billions of distinct optical barcodes, far beyond what fluorescence allows.

  2. 02

    Load

    Beads fall randomly, one per microwell, across 50,000 wells. A self-priming chip draws the sample in with a single pipette. No instruments, no fluidics.

  3. 03

    Amplify

    Each well is a sealed microreactor running standard qPCR in parallel. Compartmentalization removes the primer cross-talk that caps conventional multiplexing at ~10 targets.

  4. 04

    Decode

    A large-field-of-view imager captures every amplification curve in one shot. Software maps each barcode to its target and returns a per-gene report.

Built, run, and validated in the lab.

This is not a concept on a slide. We have demonstrated every core component (the barcoded beads, the microreactor array, and the single-shot imager) and run massively multiplexed screens against known truth.

30×faster than NGS at comparable biomarker breadth
5%of conventional reagent cost per test
132genes
screened in a single multiplexed run (synthetic genomes)
>90%
sensitivity and specificity vs. ground truth
>95%
single-bead loading rate, <5% double-loading
3,000+
spectrally unique VibrantBeads fabricated and decoded

Backed by a decade of multiplexing research · 10 patents filed, 2 published

A multi-billion-dollar market, barely tapped.

Genomic cancer testing is growing past 22% a year as targeted therapy becomes standard of care. The bottleneck is not demand. It is the cost and speed of today’s tools.

New cancer diagnoses

20M

per year, globally. Each a candidate for genomic profiling.

Current penetration

~2%

take large-panel testing today. The runway is the other 98%.

Growth

22%

CAGR across genomic cancer panels and profiling.

Germline genotyping

$2.3B
2021
$26.6B
+10 yr

Somatic genotyping

$9.3B
2022
$12.9B
+10 yr

The only platform strong on all three axes.

Others optimize for breadth or for cost. VibrantBio is the first to deliver high multiplexing, low cost, and fast turnaround at once.

PlatformMethodCost efficiencyTurnaroundMultiplexing
VibrantBioUsMultiplexed qPCR
Illumina (NGS)Sequencing
FluidigmMicrofluidic qPCR
AplexBioNucleic acid
ChromaCodeNucleic acid
Thermo, Bio-RadNucleic acid
LuminexAffinity / protein

Genomic testing, wherever care happens.

Oncology labs

Run NGS-scale tumor panels in-house in 30 minutes, without sending samples out or waiting weeks for results.

Primary & point-of-care

A pipette-and-go workflow brings broad genetic pre-screening to clinics that could never run NGS.

Reference & diagnostics labs

High-throughput, low-cost panels for large diagnostics operations. The economics to test at population scale.

Expanding toPathogen detectionAgricultural genomicsCompanion diagnostics

A clear path to the clinic.

  1. 2025

    Proof of concept

    • Chip & hardware prototype
    • Multiplexed assay demonstrated
  2. 2025-26

    Assay & validation

    • 100-plex assay development
    • 510(k) clinical trial begins
  3. 2027

    Scale

    • System & software integration
    • Mass production with manufacturer
  4. 2029

    FDA approval

    • Regulatory clearance
    • Commercial launch

Let’s talk.

Investors, partners, and labs: tell us why you’re reaching out and we’ll get back to you quickly.

info@vibrantbioscience.com